ArticleBMC cancer2018

Possible involvement of interleukin-18 in the pathology of hepatobiliary adverse effects related to treatment with ceritinib.

Taizou Hirano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.